title: New frontiers in therapeutic resistance in cancer.
abstract: Despite advances in personalized medicine and targeted therapies, therapeutic resistance remains a persistent dilemma encountered by clinicians, scientists and patients. In this article we summarize the highlights of the third Quebec Conference on Therapeutic Resistance in Cancer. This unique meeting provided researchers and clinicians with insights into: intrinsic and acquired resistance; tumor heterogeneity; complexities of biomarker-driven trials; challenges of 'omics data analysis; and models of clinical applications of personalized medicine. Emphasized throughout the conference was the importance of collaborations - between industry and academia, and between basic researchers and clinicians - so that therapeutic resistance can be studied where it matters most, in patients.
authors: Falck Division of Medical Oncology, Department of Oncology, Ospedale Niguarda Ca' Granda, Piazza Ospedale Maggiore, 3 20162 Milano, Italy. andrea.sartorebianchi@ospedaleniguarda.it
authors: Andrea
authors: A
authors: Sartore-Bianchi
authors: Mauro
authors: M
authors: Delorenzi
authors: Thérèse
authors: T
authors: Gagnon-Kugler
authors: Caroline
authors: C
authors: Rousseau
authors: Gerald
authors: G
authors: Batist
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D023281:Genomics; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D057285:Precision Medicine; D040901:Proteomics; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents